

1 Dalmore Drive,
Scoresby,
Victoria 3179
AUSTRALIA
T: +61 (0)3 9763-1287
F: +61 (0)3 9763-2817
www.generabiosystems.com

Tuesday 21 June 2016

**ASX Announcement – GENERA BIOSYSTEMS LIMITED (ASX: GBI)
INDIAN MARKET UPDATE AND REGULATORY APPROVAL**

Genera Biosystems Limited ('Genera') is pleased to announce that the Indian Central Drugs Standard Organisation (Medical Device and Diagnostic Division) has approved the importation and sale of RTI-plex, Genera's upper respiratory tract multiplex molecular diagnostics ('MDx') test, throughout India.

The license approval is now in force for a term of 3 years to June 2019 before requiring renewal. During the second half of calendar 2016 Genera and GeneCell Diagnostics, Genera's Indian distribution partner, will complete the submission for Genera's PapType HPV test on the same basis in order to achieve India-wide regulatory and importation approval.

Distribution Strategy in Indian Market

In July 2015, Genera entered into a non-exclusive distribution agreement with GeneCell Diagnostics to supply its AmpaSand based MDx assays to two selected pathology groups in the Indian market.

Under the terms of the Commercial Supply and Distribution Agreement, GeneCell has the right to distribute Genera's AmpaSand MDx assays to its CureHealth Diagnostics pathology lab subsidiary and to SRL Diagnostics. SRL is the leading and reputed national lab network in India with a 43% market share of the organised Indian pathology sector. With 258 labs (of which 12 are high-end laboratories) and 6,300 collection points, SRL has the second largest pathology network in Asia conducting more than 107,000 tests a day ranging from simple to high-end tests.

With regulatory approval now in place for RTIplex, GeneCell will commence commercial sales. CureHealth Diagnostics has completed all of required preparatory activity, including installation of instrumentation and staff training, to be the first commercial customer.

CureHealth operates a specialised pathology MDx reference laboratory in New Delhi servicing the Delhi and National Capital Region (NCR) territory markets. A close relationship exists between CureHealth and SRL Diagnostics, with CureHealth holding an exclusive marketing agreement with SRL Diagnostics for its HPV mRNA test in the cervical cancer screening domain, pan India.

CureHealth founder Dr Dinesh Gupta is a national expert in molecular diagnostics for HPV testing and is a Life Member, Indian Society of Cervical Cytology & Pathology. For over 10 years Dr Gupta was a Key Opinion Leader responsible for the promotion of the Qiagen HC2 HPV test throughout India.

Richard Hannebery, Genera Chief Executive Officer commented, "India represents an enormous opportunity for Genera as better healthcare awareness drives demand for quality pathology

services. There is a significant middle class population in India, who in consultation with their physicians want to access the most advanced diagnostic technology available. We believe GeneCell is an ideal partner to support Genera's plans to penetrate this market."

India's medical diagnostics market size is currently worth about US\$3.2 billion per annum (Rs 20,000 crore), of which 10 per cent is in the organised pathology sector with substantial market fragmentation and challenges existing outside of this space.

After leading with RTIplex Genera now plans to take its PapType HPV test through the Indian Central Drugs Standard Organisation regulatory and importation approval process. In due course, Genera envisages an Indian sales strategy that extends beyond sales to CureHealth and SRL Diagnostics to also include assay sales made via a third party global IVD Company.

Richard Hannebery commented, "While the process of readying RTI-plex for launch into the Indian market has taken longer than originally anticipated the company is now confident in the roadmap for bringing our HPV PapType test into the Indian market alongside our STIplex assays and those other high value MDx tests within our development pipeline."

Genera believes that new demand from India may smooth out the seasonality of Southern Hemisphere flu season sales which are currently ramping up to peak volumes over the next few months. The Company currently anticipates record 2016 RTIplex sales.

Extension of GeneCell Distribution to PapType and STIplex

Genera advises that it has agreed to extend the distribution rights of GeneCell to include its CE-IVD approved HPV PapType test as well as an RUO version of its STIplex sexually transmitted infections panel as soon as development is complete.


Transfer pricing for PapType has been agreed between the parties with final pricing of STIplex to be agreed in the later part of calendar 2016.

Submission of Genera tender for commercial supply of PapType into 500,000 cervical screening program

Genera has recently submitted a commercial supply tender for a significant state government funded project to screen half a million women in a rural and semi-urban district of Thane near Mumbai, over a period of 5 years. The project aims to screen 100,000 women annually and will use a combination of Visual Inspection as a primary screen followed by reflex to HPV DNA testing and thereafter reflex again to HPV RNA testing.

The program is the largest state government sponsored cervical screening program incorporating both HPV DNA and RNA testing ever undertaken within India.

Genera submitted what it believed to be a competitive tender on a USD Free on Board (FOB) basis ex-Scoresby Australia and will be advised of the outcome of the tender process within the next few months.



For further information please contact:

Mr Richard Hannebery
Chief Executive Officer
Genera Biosystems Limited
Telephone: +61 (0)3 9763 1287
www.generabiosystems.com.au

About Genera Biosystems : Genera Biosystems Limited (“GBI”) is an Australian Securities Exchange listed molecular diagnostics company, which develops, manufactures and distributes advanced PCR molecular diagnostics tests. GBI has successfully developed two products to date, PapType® and RTI-Plex™, both of which are CE-IVD approved with several additional products in the company’s development pipeline. Genera manufactures these products in its Therapeutics Goods Administration (TGA) certified manufacturing facility in Scoresby, Victoria, Australia.